Karuna Therapeutics, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020	Q1 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q3 FY2019 As of Sep 30, 2019	Q2 FY2019 As of Jun 30, 2019
Assets
Current assets:
Cash and cash equivalents
Short-term investments
Restricted cash
Investment securities, available-for-sale
Short-term investments, other
Accounts receivable
Deferred offering costs
Prepaid expenses
Other current assets
Total current assets

Restricted cash
Right-of-use lease assets - operating, net
Property and equipment, net
Other non-current assets
Total assets
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
Accrued expenses
Current portion of deferred lease obligation
Derivative liability
Current portion of operating lease liability
Deferred rent
Other current liabilities
Total current liabilities

Non-current convertible notes, net of discount
Deferred lease obligation, net of current portion
Operating lease liability, net of current portion
Other non-current liabilities
Total liabilities
Redeemable convertible preferred stock, (Series Seed, A and B) $0.0001 par value; 0 and 7,539,200 shares authorized and outstanding at December 31, 2019 and 2018, respectively
Series Seed Redeemable Convertible Preferred Stock
Series A Redeemable Convertible Preferred Stock
Series B Redeemable Convertible Preferred Stock
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and 0 shares outstanding as of December 31, 2023 and 2022
Common stock, $0.0001 par value; 150,000,000 shares authorized as of December 31, 2023 and 2022; 38,091,829 and 34,473,905 shares issued as of December 31, 2023 and 2022; 38,077,525 and 34,473,905 shares outstanding as of December 31, 2023 and 2022, respectively
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income
Accumulated other comprehensive (loss) income
Treasury stock at cost, 14,304 and 0 shares as of December 31, 2023 and 2022, respectively
Total stockholders’ equity

Total liabilities and stockholders’ equity

Comments